Study will test promising treatment to forestall kidney disease among diabetics

by Dan Browning, Star Tribune (Minneapolis)

Paul Wild has been a reliable research volunteer at the University of Minnesota for 20 years, participating in two landmark studies that changed the standard of care for diabetes, a disease that afflicts more than 24 million Americans.

"Looking back, it was probably the best thing I ever did," said the Mendota Heights dentist.

Now, Wild, 61, is among 480 patients being recruited for a $24 million, 3 {-year test to see whether a medication that has been used routinely to prevent gout can delay the onset of potentially fatal in patients with Type 1 .

If the study succeeds, the medication, called allopurinol, could be to what baby aspirin is to heart attacks, said Dr. Luiza Caramori, an endocrinologist helping to oversee the study at the university. The drug could delay the need for dialysis and kidney transplants by eight to 10 years, she said, saving thousands of lives and tens of millions of dollars in medical spending.

Diabetes has reached epidemic proportions in the United States, with rates increasing so fast that researchers predict that 1 in 3 Americans born after 2000 could develop either type 1 or type 2. As many as 30 percent of diabetics will develop serious kidney disease within 20 years of their diagnosis, making it the leading cause of in the United States. And because the waiting list for a kidney is so long, hundreds of patients die each year waiting for a transplant.

While the University of Minnesota study is limited to subjects with Type 1 diabetes, Caramori said positive findings are likely also to benefit the far more common Type 2 diabetics.

"It's amazing that in the past 20 years we've basically made no progress in delaying kidney disease in patients with diabetes," she said. "It's also disappointing and scary, because the rates of complications are quite high in these patients."

Type 1 diabetes occurs when the immune system destroys the body's ability to produce insulin. It affects fewer than 1 in 10 diabetics. The much more common Type 2 often results from genetic predisposition, coupled with obesity and lifestyle factors, leading initially to resistance to the body's own insulin.

The University of Minnesota is one of seven U.S. sites and two international locations recruiting participants for the study.

Results from three small preliminary studies indicate that allopurinol shows real promise. It suppresses the production of an enzyme, xanthine oxidase, a result of metabolic activity, which can lead to excess acid in the urine.

It's also cheap and has been used in the Untied States for nearly 50 years to prevent gout flare-ups.

The study will assign subjects randomly to two equal groups. They will get either allopurinol or a placebo - neither the patients nor their doctors will know which - and they'll have to visit a study center or a site working remotely with the centers 17 times over three years for a variety of procedures and tests.

Diabetics account for about 45 percent of people with end-stage kidney disease. Caramori said the survival rate, once they enter dialysis, is very low.

"So there's a big fight trying to bring funds to diabetes research. There's a lot of money allocated to cancer that can benefit, of course, many patients. But even more funds are allocated to AIDS, for example, where the fraction of the population that's affected is much smaller," she said. Though both diseases are important, by comparison, she said, "We are not doing well in terms of spending money in diabetes research."

4 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Team finds method for more precise diagnosis of pneumonia

15 minutes ago

A patient survives life-threatening trauma, is intubated in the intensive care unit (ICU) to support his or her affected vital functions, starts to recover, and then develops pneumonia. It's a scenario well-known to physicians, ...

Screen women for chlamydia, gonorrhea, experts say

1 hour ago

(HealthDay)—All sexually active women should be screened for two of the most common sexually transmitted infections: chlamydia and gonorrhea, according to new recommendations from the U.S. Preventive Services ...

Noninvasive devices may help migraines, FDA says

2 hours ago

(HealthDay)—Two new prescription devices approved by the U.S. Food and Drug Administration (FDA) may provide some relief for people with migraine headaches who don't tolerate migraine medications well, ...

User comments